Stream

William Domburg

Discussion  - 
 
Is this the beginning of the end of the party?
1
Add a comment...

William Domburg

Discussion  - 
 
YES !
1
Add a comment...

William Domburg

Discussion  - 
 
No update of our Blog portfolio:
1
Add a comment...

William Domburg

Discussion  - 
 
Our BLOG portfolio was slightly increasing to +24.6% y/y.
Check it on:
www.bloggen.be/wivado
1
Add a comment...
 
For a limited time only save on this promotion! If you are serious about learning options you are not going to want to miss out on this!!

http://hotstocksforincome.com/membership-details/
1
Add a comment...
 
Kennsei Trading June Newsletter http://conta.cc/1dcB0Al
1
Add a comment...

Fernando MB

Stock Analysis  - 
 
05-19-2015 TRADING IDEA $LNKD LAST PRICE 194.65 NEW TRADING ASISTANCE  REAL TIME. Hi mates how you doing. i started this month a new service for clients and investors. The service includes my trading ops in real time. buy lim...
1
Add a comment...

Curt Dalton

Discussion  - 
Apple Watch Parts Failure and Demand Downgrade From UBS, Now What For Apple? On Thursday, US markets were down significantly, bringing April to a close on a negative note. Technology stocks were responsible for much of the downdraft, including weaknesses in such bellwethers as Apple, Google and IBM.
1
Add a comment...

About this community

An investment community aimed to help the average investor understand the stock market. Ideas, reports, discussions and more. If you need or want a public company to be analyzed just drop a comment under the "Request of New Analysis" section and we'll try to get it to you in a timely manner.

Jonathan Millet

Discussion  - 
1
lamont brantley's profile photo
 
BUY&HOLD
Add a comment...

Jonathan Millet

Discussion  - 
1
Add a comment...
 
http://hotstocksforincome.com/membership-details/


If you are looking for a mentor to help teach you the  power of options....look no further!! Instead of JUST learning theory and techniques from various sources, we will show you how you can APPLY this to the actual LIVE markets. It is one thing to read something but doing it.. well that's where it gets tricky and if you make the wrong move it can cost you BIG.


So we are here to help. We have a special promotion going on right now that is for a limited time only and it will not cost you an arm and a leg to do  it. The BEST part is after you get down this skill set we will teach you, you can make it all back in one to two trades.

http://hotstocksforincome.com/membership-details/
1
Add a comment...

William Domburg

Discussion  - 
 
 
Our BLOG portfolio was slightly increasing to +24.6% y/y.
Check it on:
www.bloggen.be/wivado
Beleggen, aandelen, invest, stocks, investment, share
1
Add a comment...

William Domburg

Discussion  - 
 
TC.To

Fair Value: CAD28
Actually overvalued
Average yearly return: 61%  
Outperformer
A BUY around CAD22
1
Add a comment...

William Domburg

Discussion  - 
 
What a day for our blog portfolio:

Portfolio value: €35,891.61
Day's gain: +795.73 (2.27%)
Overall return: 29.53%
1
Add a comment...

William Domburg

Discussion  - 
 
Analysts Disagree Over Significance of Akorn, Inc.’s Financial Errors (AKRX)
April 28, 2015 7:30 AM EDT in Contributor Opinions • Industrial
Akorn, Inc. (NASDAQ:AKRX) announced on Friday that it will have to restate financials from 2014 due to accounting errors. Akorn warned that their financial reports for 2014, filed by KMPG, should not be relied upon. Though the pharmaceutical company affirmed its 2015 earnings per share guidance, the stock fell by more than 20% on Monday following the announcement.

Akorn identified the 2014 accounting missteps when reviewing financials for the first quarter of 2015. The miscalculations stemmed from understatements of rebates and other sales allowances. Though the company is still determining the exact impact of the miscalculations, initial estimates believe the errors resulted in a $20 million to $35 million overstatement of net revenue and pre-tax income for the full-year 2014.

Consequently, Akorn warned investors that it does not expect to file its quarterly report by the SEC deadline. However, Akorn affirmed guidance for 2015 earnings, expecting to post adjusted diluted EPS between $1.88 and $1.98.

On April 27, Akorn announced recent executive appointments including Randall Pollard who was appointed Corporate Controller. In this role, Pollard will oversee all accounting and financial reporting.

Analysts weighed in on the impact the flawed accounting will have on the pharmaceutical company.

On Monday, analyst David Steinberg reaffirmed a Buy rating on Akorn, though he did not provide a price target. Steinberg does not think the accounting errors will have a significant impact on the stock. He has rated Akorn once before on April 20, when he set a $56 price target for the stock. He was bullish on Akorn because he believed its clobetasol cream was more successful than that of Actavis’s.

Since David Steinberg has only rated Akorn once before on April 20, he has a 100% success rate recommending the stock with a +1% average return. Overall, David Steinberg has an 81% success rate recommending stocks with a +24.5% average return per rating.

Separately, analyst David Amsellem of Piper Jaffray downgraded Akorn from Overweight to Neutral with a price target of $53. Amsellem commented, “Though management does not believe the accounting issues will impact 1Q15 results, and it is sticking with its 2015 guidance, there is in our view far too large of a credibility gap to simply take those statements at face value.” Amsellem believes the company has lost credibility to the point that Akorn must replace its CFO.

David Amsellem has rated Akorn four times since July 2012, earning a 67% success rate recommending the company with a +25% average return per AKRX rating. Overall, Amsellem has an 80% success rate recommending stocks with a +23.7% average return per recommendation.

On average, the top analyst recommendation for Akorn on TipRanks is Hold.
1
Add a comment...